Related Experiment Videos
A microtiter solid-phase radioimmunoassay for platelet-associated immunoglobulin G
The Journal of Laboratory and Clinical Medicine
|March 1, 1983
Summary
A novel assay, the microparticle-bound specific protein radioimmunoassay (MSPRIA), accurately measures platelet-associated immunoglobulins (PAIgG). Sonicated platelets and ACD-A anticoagulant improve diagnostic sensitivity for immune thrombocytopenias.
Area of Science:
- Immunology
- Hematology
- Assay Development
Background:
- Platelet-associated immunoglobulins (PAIgG) are crucial biomarkers in immune thrombocytopenias.
- Accurate and sensitive measurement of PAIgG is essential for diagnosis and management.
Purpose of the Study:
- To describe and validate a new assay, the microparticle-bound specific protein radioimmunoassay (MSPRIA), for quantifying PAIgG.
- To compare the efficacy of different anticoagulants and platelet preparations for PAIgG measurement.
Main Methods:
- Development of a competitive inhibition radioimmunoassay using radiolabeled antibodies.
- Estimation of PAIgG using calibration curves derived from soluble IgG inhibitors.
- Comparative analysis of ACD-A versus other anticoagulants and sonicated versus intact platelets.
Main Results:
- The MSPRIA demonstrated antibody class-specificity for IgG with a coefficient of variability between 6% and 20%.
- The assay proved more sensitive than previously described methods.
- ACD-A was identified as the preferred anticoagulant, and sonicated platelets significantly increased the detection rate of elevated PAIgG in immune thrombocytopenias (87% vs. 60% in ITP patients).
Conclusions:
- The MSPRIA is a sensitive and specific method for measuring PAIgG.
- Utilizing sonicated platelets and ACD-A anticoagulant enhances the diagnostic utility of the MSPRIA for immune thrombocytopenias.